O'Brien RJ, (2001) The need for new drugs against tuberculosis:obstacles,opportunities,and next steps,

Cole ST, (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence,

Telenti A, (1997) Genetics of drug resistance in tuberculosis, WB Saunders

Lew WJ, (2005) The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations,

American Thoracic Society/Centers for Disease Control and Prevention, (2003) Infectious Diseases Society of America: Treatment of Tuberculosis,

Joia SM, (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis,

Tuberculosis Research Centre, (2002) Shortening short course chemotherapy:A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase,

Cambau E, (1996) Resistance to quinolones in mycobacteria,

Gosling RD, (2003) The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis,

T.R. Sterling, (2004) The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls,

Shim TS, Seoul Asan Medical Center (personal communication),

Stover CK, (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis,

(2000) Vaccination to prevent tuberculosis and immunomodulatory therapy for persons with active disease, Lippincott Williams & Wilkins

Han SK, (2002) The up-to-date of tuberculosis treatment. The annual course for respiratology 2002, Hanyang Medical School

Kim EK, (2004) The adjuvant effect of subcutaneous Interferon-gamma in the treatment of refractory multidrug-resistant pulmonary tuberculosis,

Park SK, (2003) Treatment of multidrug-resistant pulmonary tuberculosis with Interferon-gamma subcutaneous injection,

Koh WJ, (2001) The therapeutic effect of 6-month inhaled Interferon-gamma treatment in intractible multi-drug resisdtant pulmonary tuberculosis,

Giosue S, (1998) Effects of aerosolized interferon-αin patients with pulmonary tuberculosis,

Onyebujoh PC, (1999) Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis:a randomised controlled trial,

Jane MT, (1995) Thalidomide treatment reduces TNF-α production and enhances weight gain in patients with pulmonary tuberculosis,

Wallis RS,, (1996) Pentoxifylline therapy in HIV-seropositive persons with tuberculosis: a randomized, controlled trial,

Ha SJ, (2005) Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis,

Horwitz MA, (2000) Recombinant bacillus Calmette-Guerin(BCG)vaccines expressing the Mycobacterium tuberculosis 30-kDA major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model,

Hans L Rieder, (2002) Interventions for tuberculosis control and elimination,

Michael H Cynamon, (2001) Chemotherapeutic agents for Mycobacterial infections, CRC Press